Key result
Recombinant capsid protein vaccines and antiviral drugs for human noroviruses are advancing in development, aided by recent improvements in cell culture systems.
This review summarizes recent advances in the development of vaccines and antiviral drugs for human noroviruses.
Answers are grounded in this paper and cite their sources.
No immediate change to norovirus management; leaves open accelerated vaccine and antiviral development pending clinical trials.
Human noroviruses (HuNoVs) are a leading cause of acute, nonbacterial gastroenteritis worldwide. The lack of a cell culture system and smaller animal model has delayed the development and commercial availability of vaccines and antiviral drugs. Current vaccines rely on recombinant capsid proteins, such as P particles and virus-like particles (VLPs), which have been promising in clinical trials. Anti-HuNoV drug development is another area of extensive research, including currently available antiviral drugs for other viral pathogens. This review will provide an overview of recent advances in vaccine and antiviral development. The implication of recent advances in HuNoV cell culture for improving vaccine and antiviral development is also discussed.
No takes yet. Share an insight, caveat, or question.
Kocher et al. (2015) conducted a review in Human noroviruses (HuNoVs) / acute, nonbacterial gastroenteritis. Norovirus vaccines and antiviral drugs was evaluated. Recombinant capsid protein vaccines and antiviral drugs for human noroviruses are advancing in development, aided by recent improvements in cell culture systems.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: